Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Bone Marrow Transplantation, Published online: 21 October 2019; doi:10.1038/s41409-019-0718-7In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpre...
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research

Related Links:

We report here a series of children who developed pulmonary hypertension after HSCT. Methods Between January 2008 and December 2015, we retrospectively analysed 366 children who underwent HSCT (age range 0.5–252 months; median 20.3 months). During the post-HSCT course, echocardiography scans motivated by respiratory symptoms identified 31 patients with elevated tricuspid regurgitation velocity (>2.8 m·s–1), confirmed when possible by right heart catheterisation (RHC). Results 22 patients had confirmed pulmonary hypertension with mean±sd pulmonary arterial pressure 40.1±1...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Pulmonary vascular disease, Paediatric pulmonology Original Articles: Pulmonary hypertension and paediatrics Source Type: research
Bone Marrow Transplantation, Published online: 21 November 2019; doi:10.1038/s41409-019-0740-9Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 21 November 2019; doi:10.1038/s41409-019-0755-2Clinical characteristics of human herpesvirus-6 myelitis after allogeneic hematopoietic stem cell transplantation and its favorable outcome by early intervention
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Authors: Kwon Y, Lee KW, Park H, Son JK, Lee J, Cho CW, Kwon GY, Park JB, Kim SJ Abstract Bone marrow preconditioning using cyclophosphamide (CP) is generally used for bone marrow transplantation (BMT). However, because of CP's hepatotoxicity and nephrotoxicity, additional fludarabine (FDR) administration and a reduced dose of CP are used for reduced-intensity preconditioning. Recently, preclinical studies using non-human primates (NHPs) were performed to induce immune tolerance after solid organ transplantation by conducting BMT simultaneously. However, dose optimization of CP and FDR for BMT preconditioning in cy...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Bone Marrow Transplantation, Published online: 19 November 2019; doi:10.1038/s41409-019-0746-3Predictors of the trajectory of cognitive functioning in the first 6 months after allogeneic hematopoietic stem cell transplantation
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 19 November 2019; doi:10.1038/s41409-019-0745-4Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 19 November 2019; doi:10.1038/s41409-019-0752-5Clinical practice recommendations for the diagnosis and management of human herpesvirus-6B encephalitis after allogeneic hematopoietic stem cell transplantation: the Japan Society for Hematopoietic Cell Transplantation
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 19 November 2019; doi:10.1038/s41409-019-0751-6Outcomes of haploidentical haematopoietic stem cell transplantation for paroxysmal nocturnal haemoglobinuria
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 19 November 2019; doi:10.1038/s41409-019-0747-2Evaluating the clinical effectiveness of autologous haematopoietic stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching-adjusted indirect comparison: an exploratory study from the Autoimmune Diseases Working Party (ADWP) of the European Society of Bone and Marrow Transplantation (EBMT)
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
Bone Marrow Transplantation, Published online: 18 November 2019; doi:10.1038/s41409-019-0744-5Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Australia Health | Belgium Health | Bone Marrow Transplant | France Health | Germany Health | Hematology | Italy Health | Spain Health | Statistics | Stem Cell Therapy | Stem Cells | Switzerland Health | Transplants | UK Health